Biotinylated Human IL-17A&17F Protein (C-Avi-6His)

Beta LifeScience SKU/CAT #: BL-2736NP
BL-2736NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-2736NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Biotinylated Human IL-17A&17F Protein (C-Avi-6His)

Beta LifeScience SKU/CAT #: BL-2736NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Biotinylated Recombinant Human Interleukin-17A/ Interleukin-17F Heterodimer is produced by our Mammalian expression system and the target gene encoding Gly24-Ala155&Arg31-Gln163 is expressed with a Avi tag and a 6His tag at the C-terminus.
Accession Q16552&AAH70124.1
Synonym IL‑17A/F Heterodimer; IL-17A&IL-17F Heterodimer
Gene Background Human IL-17A&IL-17F is an disulfide-linked heterodimeric glycoprotein comprised of two members of the IL-17 family of cytokines, IL-17A and IL-17F .IL-17A and IL-17F bind to a receptor complex consisting of two IL-17RA chains and one IL-17RC subunit. Genes encoding IL-17A and IL-17F are located on chromosome 6 (6p12) and polymorphisms in these genes were studied in various autoimmune diseases. Previous studies have demonstrated that the G allele of the IL17A gene polymorphism is associated with significantly impaired long-term kidney allograft function and that the GA genotype of the IL17F gene polymorphism is associated with a significantly higher risk of a return to dialysis after kidney transplantation. It’s also reported that IL17A gene polymorphism was associated with significantly impaired long-term kidney allograft function, whereas the GA genotype of the IL17F gene polymorphism with a significantly higher risk of graft function loss and return to dialysis after kidney transplantation.
Molecular Mass 15.1&17.8 KDa
Apmol Mass 15-22 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 6% Sucrose, 4% Mannitol, 100mM NaCl, 0.05% Tweem 80, pH 7.5.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Biologically active. Please contact us to obtain bioactivity data.
Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed